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INTRODUCTION
Pharyngitis is one of the most common 
reasons for consulting a GP. Over the winter 
period, around 6% of GP consultations in the 
UK tend to be for patients presenting with 
a sore throat, which represents more than 
3.5 million consultations.1 Although, in many 
cases, pharyngitis has a viral aetiology, 20%–
35% of cases may be caused by bacteria 
— specifically, group A beta-haemolytic 
streptococcus (GABHS).2,3 Worldwide, 
infection with group A streptococci (GAS) 
places a significant burden on global health, 
and around 500 million people will die from 
GAS-related diseases each year.4 
In order to stratify patients most at risk 
of GABHS, the Centor score was developed. 
Each of four clinical features — absence 
of cough, purulent pharyngeal exudate, 
anterior cervical lymphadenopathy, and 
temperature of >38°C — is scored with 1 
or 0, depending on whether it is present;5 
scores range from 0 (when none of the 
features are present) to 4 (when all are 
present). In the original study, conducted 
in an emergency department in the US, a 
score of 3 was associated with a 30.1%–
34.1% probability of GABHS.5 McIsaac 
independently derived a prediction system 
based on a cohort of patients from primary 
care.6 In essence, it modifies the Centor 
system to include an extra variable — 
age. For those aged between 3 years and 
14 years, 1 is added to the score, whereas, 
for those aged ≥45 years, 1 is subtracted 
from the score; hence, a patient presenting 
with a sore throat may have a McIsaac 
score of anything between –1 and 5.6 
Many health systems have recommended 
the use of Centor or McIsaac scores in 
their guidelines to help manage patients 
with acute pharyngitis.7–10 In the UK, the 
Centor score is one of two prediction rules 
recommended by the National Institute 
for Health and Care Excellence (NICE).10 
Although the extent to which these rules 
are used in UK general practice is unclear, 
a recent survey of 266 GPs in Denmark 
reported that approximately half used the 
Centor score and 15% used the McIsaac 
score — this was in spite of the fact that the 
McIsaac score is the recommended rule in 
Denmark for diagnosing GABHS.9
The question of which rule is likely to 
yield the most accurate diagnosis of 
GABHS for patients presenting to general 
practice is difficult to answer based on 
existing research. Only one primary study 
to date — reported in two articles by Fine 
et al11,12 — provides the data to allow a direct 
comparison. Furthermore, comparisons 
at individual thresholds are meaningless, 
as those thresholds are not equivalent to 
each other — for example, a Centor score 
of 3 is not equivalent to a McIsaac score of 
3, as the latter is calculated with an extra 
variable (that of age). To compare the tests, 
an overall assessment across all thresholds 
is required, such as may be provided by a 
receiver operating characteristic (ROC) curve.
Although meta-analysis allows the 
aggregation of multiple studies, either to 
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Comparison of Centor and McIsaac scores 
in primary care:
a meta-analysis over multiple thresholds
Abstract
Background
Centor and McIsaac scores are both used 
to diagnose group A beta-haemolytic 
streptococcus (GABHS) infection, but have not 
been compared through meta-analysis.
Aim
To compare the performance of Centor and 
McIsaac scores at diagnosing patients with 
GABHS presenting to primary care with 
pharyngitis.
Design and setting
A meta-analysis of diagnostic test accuracy 
studies conducted in primary care was 
performed using a novel model that 
incorporates data at multiple thresholds.
Method
MEDLINE, EMBASE, and PsycINFO were 
searched for studies published between January 
1980 and February 2019. Included studies were: 
cross-sectional; recruited patients with sore 
throats from primary care; used the Centor or 
McIsaac score; had GABHS infection as the 
target diagnosis; used throat swab culture 
as the reference standard; and reported 2 × 2 
tables across multiple thresholds. Selection 
and data extraction were conducted by two 
independent reviewers. QUADAS-2 was used 
to assess study quality. Summary receiver 
operating characteristic (SROC) curves were 
synthesised. Calibration curves were used to 
assess the transferability of results into practice.
Results
Ten studies using the Centor score and eight 
using the McIsaac score were included. The 
prevalence of GABHS ranged between 4% 
and 44%. The areas under the SROC curves 
for McIsaac and Centor scores were 0.7052 
and 0.6888, respectively. The P-value for the 
difference (0.0164) was 0.419, suggesting the 
SROC curves for the tests are equivalent. Both 
scores demonstrated poor calibration.
Conclusion
Both Centor and McIsaac scores provide only 
fair discrimination of those with and without 
GABHS, and appear broadly equivalent in 
performance. The poor calibration for a positive 
test result suggests other point-of-care tests 
are required to rule in GABHS; however, with 
both Centor and McIsaac scores, a score of ≤0 
may be sufficient to rule out infection.
Keywords
Centor score; diagnosis; McIsaac score; meta-
analysis; pharyngitis; primary health care.
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produce a summary (sensitivity, false positive 
rate) point or a summary ROC curve,13–15 
both of these methods are constrained by 
the inclusion of only one (sensitivity, false 
positive rate) data point per study, where 
the false positive rate = 1 – specificity. When 
a study reports data at multiple thresholds, 
an arbitrary choice has to be made on which 
threshold to use when extracting the data 
for meta-analysis. Recent developments 
in meta-analysis methods allow this 
constraint to be relaxed so, if individual 
studies provide data at multiple thresholds, 
all of the data may be included for analysis;16 
as such, the unit of interest for each study 
becomes its ROC curve and not just an 
individual (sensitivity, false positive rate) pair. 
This provides the basis for generating a 
summary ROC (SROC) curve for the Centor 
and McIsaac scores based on all the data 
reported in the primary studies.
This study aimed to compare the 
performance of Centor and McIsaac 
scores in diagnosing patients with GABHS 
presenting to primary care with a sore throat.
METHOD
Data sources and searches
MEDLINE, EMBASE, and PsycINFO were 
searched for relevant studies; the search 
terms used are given in Supplementary 
Box S1. The data were supplemented by a 
manual review of the references from two 
published meta-analyses — one by Aalbers 
et al,17 the other by Willis and Hyde.18 The 
grey literature was not specifically searched 
because of a lack of evidence supporting its 
use in test accuracy reviews;19,20 however, for 
completeness, a Google Scholar search was 
also performed using the terms ‘McIsaac 
score’ and ‘Centor score’. The searches were 
limited to studies published between January 
1980 and February 2019. No restrictions 
were placed on the language of publication. 
Duplicate references were discarded to get a 
cohesive set of studies ready to be reviewed 
for inclusion.
Study eligibility criteria
Studies were included if:
•	 the study was a cross-sectional primary 
study;
• the study population consisted of 
unselected patients presenting with a 
sore throat to primary care;
• the study evaluated at least one of Centor 
or McIsaac scores;
• the target diagnosis was GABHS;
• the reference standard was culture from 
a throat swab; and 
• sufficient data were reported to complete 
the 2 × 2 table for as many thresholds as 
possible.
Two researchers independently screened 
the title and abstracts of all citations 
identified. Full texts were obtained for 
those articles not excluded at the screening 
stage, and the same two investigators 
independently assessed the studies for 
eligibility based on the above criteria. 
Disagreements were resolved through 
discussion and achieving consensus. 
Data collection and quality assessment
Data were extracted on the following study 
characteristics:
• aim;
• test evaluated;
• start and end date; 
• method of subject recruitment;
• study location;
• description of study population;
• sample size;
• reference standard;
• conclusion of study authors;
• 2 × 2 contingency table data (true 
positives, false positives, true negatives, 
and false negatives) for each reported 
threshold on a per-patient basis; and 
• any conflicts of interest.
How this fits in 
In many healthcare systems, the Centor 
score and McIsaac score are used by GPs 
and primary care professionals to diagnose 
group A beta-haemolytic streptococcus 
(GABHS); however, there is no previous 
meta-analysis that has compared their 
performances in primary care. This 
comparative meta-analysis demonstrates 
that the Centor score and McIsaac 
score have broadly similar performance 
characteristics in diagnosing GABHS 
infection in primary care. A score of ≤0 
when using either system may have a role 
in ruling out GABHS infection in primary 
care; however, neither score is sufficiently 
accurate to rule in GABHS infection and, 
if applied as recommended, could lead 
to more than one in two patients being 
prescribed antibiotics inappropriately. 
Other point-of-care diagnostics that 
augment these scores are needed if rates 
of inappropriate antibiotic prescribing are 
to be reduced.
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The quality of each included study was 
assessed using the Quality Assessment of 
Diagnostic Accuracy Studies (QUADAS-2) 
tool,21 which assesses the risk of bias 
across a number of domains. The category 
‘unclear’ was used when there was 
insufficient information reported in the 
study to come to a clear decision even after 
discussion.
The same two researchers who screened 
the initial abstracts independently extracted 
data, and performed the appraisal 
and quality assessment of each study. 
Disagreements were resolved through 
discussion and achieving consensus.
Synthesis and meta-analysis methods
The Different random Intercept Different 
random Slope (DIDS) model from the R 
package diagmeta (https://CRAN.R-project.
org/package=diagmeta) was used to fit the 
data from the primary studies. This fits two 
linear mixed models — one for the false 
negative rate and one for the specificity — 
using the study as the grouping factor and 
allowing data from multiple thresholds for 
each study. Each linear mixed model has 
a random intercept and random gradient 
term, and the four random effects are 
assumed to have a four-dimensional 
multivariate normal distribution;16 these are 
used to generate an SROC curve. 
An SROC curve and C-statistic (area 
under the curve [AUC]) was generated for 
Centor and McIsaac scores. Positive and 
negative likelihood ratios were derived 
for each of the thresholds with bootstrap 
confidence intervals (CIs). Assuming a 
null hypothesis that there is no difference 
between the C-statistics, the null 
distribution was derived empirically using 
a bootstrap sample of 1000. The level of 
significance was set to 0.05. For each test, 
the summary (sensitivity, false positive rate) 
pair corresponding to each threshold was 
also derived. Calibration plots of expected 
probabilities versus observed probabilities 
were derived for positive and negative 
test results after fitting an additive model 
to the logits of these probabilities using 
cubic splines.22 Each plot was corrected for 
optimism using a bootstrap sample of 1000 
as recommended by Harrell.23
RESULTS
Study selection
The searches identified 80 citations. The 
full selection process (outlined in Figure 1) 
resulted in 18 studies2,6,11,12,24–37 being 
included in the review; 10 of these used 
the Centor score2,11,12,24–31 and eight used 
the McIsaac score.6,11,12,32–37 Only one study 
— reported by Fine et al11,12 — provided 
sufficient data to allow a direct comparison 
between the two tests.
A flowchart of the primary studies’ 
selection decisions is given in Figure 1.
Study characteristics
Full study characteristics are detailed 
in Table 1. Of those studies using the 
Centor score, eight were conducted in 
Europe2,24–27,29–31 and two in the US.11,12,28 
Of those studies using the McIsaac score, 
three were conducted in Europe,32,33,36 
four in North America,6,11,12,35,37 and one in 
Australia.34 Three studies were translated 
from Spanish.26,31,36 The only study to provide 
data on both the Centor and McIsaac scores 
(Fine et al11,12) had a sample size that was 
more than 100 times larger than the next-
largest study.
The median prevalence of GABHS for the 
studies using the Centor score was 26.4% 
(range: 4.7%–42.0%); for studies using 
the McIsaac score, it was 23.0% (range: 
12.7%–44.8%). Exactly half of the studies 
using the Centor score provided data on all 
thresholds, and all studies provided data for 
two or more thresholds. A quarter of studies 
using the McIsaac score provided data on 
all thresholds, and all studies provided data 
for ≥4 thresholds. The ROC curves for each 
of the studies using the Centor score are 
shown in Figure 2; those for each of the 
studies using the McIsaac score are given 
in Figure 3. 
For two of the included studies using the 
McIsaac score, McIsaac was listed as the 
lead author.6,37
Risk of bias and applicability
There is no validated statistic for measuring 
between-study heterogeneity across ROC 
curves; however, Figure 2 and Figure 3 
show that, for both tests, the ROC curves 
are widely distributed; this suggests there 
is heterogeneity between studies for both 
tests.
For many of the studies,2,6,25–28,30–35,37 the 
reporting was inadequate, which introduced 
uncertainty when assessing the risk of 
bias — for example, the method of patient 
selection was not always described and it 
was not always clear whether any subjects 
had been excluded. Often, it was not 
reported whether the reference standard 
was carried out blind to the test results, 
although it is unclear whether knowledge 
of the test results would have greatly 
influenced the results of a cultured throat 
swab. In general, the study populations 
were considered representative of those 
seen in the different forms of primary care. 
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In two studies31,37 there were discrepancies 
between the number of subjects recruited 
and the number used in analyses, thereby 
increasing risk of biased estimates for the 
statistics of interest. In addition, although 
in one study that used the Centor score the 
target condition was largely GABHS, it also 
included group C and group G streptococcal 
infection as the target condition.25 This could 
potentially affect the applicability of the 
findings of this study. QUADAS-2 results are 
given in Supplementary Figure S1 (McIsaac 
score) and Supplementary Figure S2 
(Centor score).
Synthesis of results
The sensitivities, specificities, and positive 
and negative likelihood ratios for each 
threshold are given for both scores in 
Table 2. Figure 4 shows the SROC curves 
for the Centor and McIsaac scores, with 
points on each curve corresponding to 
particular thresholds; it is clear that the 
curves are very close to each other and 
this is confirmed by the C-statistic. For the 
Centor score, the C-statistic was 0.6888 
(95% CI = 0.653 to 0.724) and for McIsaac’s 
score it was 0.7052 (95% CI = 0.624 to 0.778); 
the 95% CIs are for the sensitivity given the 
specificity. From the empirical distribution 
of the difference between C-statistics, a 
difference of 0.0164 has a corresponding 
P-value of 0.419; this suggests there is no 
statistically significant difference between 
the C-statistics for the two curves.
Two post-hoc sensitivity analyses were 
carried out. The first investigated the effect 
of excluding the largest study (that by Fine 
et al11,12 and resulted in the C-statistics 
for the Centor and McIsaac scores being 
0.6724 (95% CI = 0.610 to 0.731) and 0.7167 
(95% CI = 0.632 to 0.788), respectively. As 
such, the effect is to decrease the C-statistic 
for the Centor score and to increase it for 
the McIsaac score. Again, the difference 
(0.0443) was not statistically significant 
(P = 0.188). In the second analysis, it 
was noted that two of the eight included 
studies that used the McIsaac score 
were led by the researcher who proposed 
it (namely, McIsaac);6,37 as such, only six 
studies evaluated the score independently. 
A sensitivity analysis was conducted in 
which the two studies led by McIsaac were 
excluded to evaluate the overall effects on 
the C-statistic. The C-statistic for the six 
independent studies was 0.6700 — lower 
than that when all studies were included in 
the analysis (0.7052) and that for the Centor 
score (0.6888).
The calibration plot for the post-test 
probabilities after a positive test result 
(positive predictive value [PPV]) for both 
scores, after correcting for optimism, is 
shown in Figure 4. The curves broadly 
coincide, with overfitting being particularly 
evident for expected PPVs above 0.5. 
Supplementary Figure S3 shows the 
calibration plot for the post-test probabilities 
for a negative test result after correcting 
for optimism. Here, the Centor score 
demonstrates better calibration than the 
McIssac score. For the derivation of both 
calibration plots, the prevalence of GABHS 
is assumed to be known. 
Whether either test could be used to 
rule in, or rule out, infection is not fully 
addressed by the AUC. For a GABHS 
infection prevalence of 25%, using Bayes’ 
theorem the expected PPV for a McIsaac 
score of 5 is 59%; however, from the 
calibration curve this expected PPV is likely 
Figure 1. Flow chart of studies selected.
EMBASE
citations = 60
PsycINFO
citations = 0
MEDLINE
citations = 44
2 reviews
citations = 21
Google Scholar
citations = 1
Unduplicated
citations = 80
Unable to retrieve:
full text = 5
Excluded: not in
primary care = 22
Excluded: Centor/
McIsaac not
evaluated = 10
Excluded: score used
to select subjects = 6
Excluded: gold 
standard not throat
culture = 2
Excluded: case
studies/reviews = 8
Included articles = 18
Centor = 10
McIsaac = 8
Abstracts
screened = 80
Full-text review = 66
Excluded: not
relevant = 9
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Table 1. Study characteristics
     Age,   Prevalence, 
Study Location Score Year Setting years Sample % Thresholds Reference standard
Alper24 Bursa,  Centor May 2007 to  Emek Family 7–86 282 11.4 0,1,2,3,4 Throat culture 
 Turkey  Apr 2008 Practice Centre
Fine11,12 26 states Centor/ 1 Sep 2006 to  Around 581 3–≥55 206 870 27.1 0,1,2,3,4 DNA probe and 
 in US McIsaac 1 Dec 2008 minute clinics     –1,0,1,2,3,4,5 throat culture for 
    in CVS chain      RADT negatives,  
    across 26 states     RADT for test 
         positives
Little25 UK Centor Jan 2007 to General practices ≥5 1086 33.7 0,1,2,3,4 Throat culture 
   Oct 2008
Marin Cañada26 Madrid, Spain Centor 14 Feb 2005 to San Fernando 2 14–81 140 24.2 0,1,2,3,4 Throat culture 
 (Spanish)  12 May 2005 Health Centre
Lindbæk27 Stokke &  Centor Apr 2000 to 1 general Children  300 42.0 0,1,2,3,4 Throat culture 
 Kongsberg,  Jun 2002 practice in and adults  
 Norway   Stokke and 
    1 in Kongsberg
Atlas28 Massachusetts,  Centor 1 Jul 2002 to 2 primary care Adults 148 25.7 0,2,3,4 Throat culture 
 US  30 Jun 2003 centres in 
    Massachusetts 
    General Hospital
Chazan29 Nazareth,  Centor Dec 1999 to Primary care 16–80 204 24.5 0,2,4 Throat culture 
 Israel  Mar 2000 clinics of the 
    Clalit Health 
    Services
Seppälä30 Turku,  Centor Jan 1986 to Private health 15–62 106 4.7 0,3,4 Throat culture 
 Finland  Mar 1986 centre Pulssi
Regueras Asturias, Spain Centor Jan 2008 to 5 primary care 2–14 192 38.5 0,3 Throat culture 
De Lorenzo31 (Spanish)  May 2010 centres
Dagnelie2 Utrecht,  Centor 1990 to 1992 53 GPs in 4–60 558 32.8 0,3 Throat culture 
 Netherlands   general practice
Stefaniuk32 Warsaw,  McIsaac Mar 2014 to Orlik General 1–≥40 96 44.8 1,2,3,4,5 Throat culture 
 Poland  May 2014 Practice 
Mistik33 Kayseri,  McIsaac Jun 2013 to Bunyamin 3–85 624 12.7 –1,0,1,2,3,4,5 Throat culture 
 Turkey  Jun 2014 Somyurek 
    Family Medicine 
    Centre
Dunne34 Melbourne,  McIsaac Winter/spring 3 general 3–72 127 18.9 –1,1,2,3,4 Throat culture 
 Australia  of 2011 and practices & ED     and PCR 
   2012 in tertiary 
    hospital
Tanz35 Chicago and McIsaac 15 Nov 2004 to 6 community- 3–18 1848 29.9 0,1,2,3,4,5 Throat swab culture,  
 Cincinnati,   15 May 2005 based paediatric     6 had RADT 
 US   offices
Flores Mateo36 Barcelona,  McIsaac Mar 2008 to 2 primary care 1–14 211 34.1 0,3,4,5 Throat culture 
 Spain  May 2009 centres in 
 (Spanish)   Castelldefels
McIsaac37 Ontario,  McIsaac Oct 1998 and 97 family Children  580 17.2 –1,1,2,3,4 Throat culture 
 Canada  Mar 1999 physicians from and adults 
    49 communities
McIsaac6 Toronto,  McIsaac Dec 1995 to University-affiliated 3–76 503 12.9 –1,1,2,3,4 Throat culture 
 Canada  Feb 1997 family medicine 
    centre
ED =  emergency department. PCR = polymerase chain reaction. RADT = rapid antigen detection test.
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to translate into an observed PPV of around 
49% (Figure 5). Thus, if a score of 5 is used 
as the threshold for prescribing antibiotics, 
a PPV of 49% translates into more than 
one in two patients receiving antibiotics 
unnecessarily. Although the expected PPV 
would increase with GABHS prevalence, 
the calibration curves show this would not 
substantially affect the observed PPV; as 
such, neither test is effective at ruling in 
GABHS.
These results lead to the question of 
whether these criteria can be used to rule 
out infection. For a McIsaac score threshold 
of 1, a negative test corresponds to a score 
of –1, or 0. Similarly, at a threshold of 0, 
a negative test is a score of –1. From 
Table 2, the negative likelihood ratios (LR–) 
for the McIsaac score at thresholds 0 and 
1 are 0.15 and 0.23, respectively. Thus, at a 
prevalence of GABHS infection of 25%, from 
Bayes theorem, low McIsaac scores such 
as –1 and 0 give expected probabilities of 
infection of 4.8% and 7.1%. Equally, for the 
same prevalence, a Centor score of 0 gives 
an expected probability of infection of 8.1%. 
For low probabilities, the corresponding 
calibration curves are more erratic for 
the McIsaac score than the Centor score 
(Supplementary Figure S3), so it is not 
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Figure 2. Centor score: ROC curves for each of the 
included studies. Each line corresponds to a single 
study and each dot corresponds to the (sensitivity, 1 – 
specificity) pair at a particular threshold for that study. 
ROC = receiver operating characteristic.
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Figure 3. McIsaac score: ROC curves for each of the 
included studies. Each line corresponds to a single 
study and each triangle corresponds to the (sensitivity, 
1 – specificity) pair at a particular threshold for that 
study. ROC = receiver operating characteristic.
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clear how well these expected probabilities 
translate into practice. Nonetheless, given 
a shared decision between GP and patient 
on what constitutes an acceptable risk of 
GABHS, a low score on either criteria may 
be considered as sufficient evidence not to 
pursue treatment or further investigation.
DISCUSSION
Summary
This is the first meta-analysis to compare 
the performances of the Centor and 
McIsaac scores in a primary care setting 
over multiple cut points. Although there 
were 10 studies that evaluated the Centor 
score and eight that evaluated the McIsaac 
score, only one primary study provided data 
that allowed a direct comparison of the two 
tests.
The meta-analysis demonstrated that 
the SROC curves were broadly aligned, 
with the curve for the McIsaac score lying 
slightly above that for the Centor score 
(see Figure 4); however, the difference was 
marginal and no statistically significant 
difference between the AUCs was found. 
Moreover, when those studies authored by 
McIsaac were excluded, a sensitivity analysis 
revealed that the AUC for the McIsaac 
score may be overstated. Nonetheless, this 
did not alter the conclusion that the two 
prediction scores have similar performance 
characteristics and that adding an age 
variable does not appear to improve the 
accuracy of the Centor score for diagnosing 
GABHS in primary care. When compared 
with the Centor system, the McIsaac 
rule changes the operating points on the 
SROC curve rather than improving on 
discrimination. In addition, with AUCs of 
approximately 0.7, both systems appear 
to be, at best, fair at differentiating those 
patients who have GABHS from those who 
do not. 
The calibration of the models for both 
scores demonstrates over-confidence, with 
the expected PPVs diverging substantially 
from the observed PPVs for probabilities of 
>40%. The effect of this is that an expected 
PPV of 80% translates into an observed 
PPV of 55%. Furthermore, these plots 
are ‘best cases’ as they are based on the 
prevalence of GABHS being known for the 
setting. When the prevalence is unknown, 
the average across all studies may be used; 
however, in the studies that were included 
in this review, the prevalence of GABHS 
ranged between 4.7% and 44.8%, so using 
the average prevalence would likely lead to 
poorer calibration as a result.
Strengths and limitations 
All of the studies provided data at 
≥2 thresholds, justifying the approach of 
using a model that accommodates both 
multiple cut points and different numbers 
of cut points between studies. This allowed 
the two criteria to be compared across the 
whole of the ROC space. Furthermore, by 
using calibration plots, it was possible to 
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Figure 4. SROC curves for the McIsaac and Centor 
scores. SROC = summary receiver operating 
characteristic.
Table 2. Sensitivity and specificity of the Centor and McIsaac scores 
at different thresholds
Threshold Sensitivity, % (95% CI) Specificity, % (95% CI) LR+ (95% CI) LR– (95% CI)
Centor score
1 97.2 (96.4 to 97.8) 10.1 (6.3 to 15.2) 1.08 (1.05 to 1.14) 0.28 (0.23 to 0.45)
2 84.4 (81.4 to 87.0) 36.7 (28.8 to 45.1) 1.33 (1.19 to 1.50) 0.43 (0.39 to 0.55)
3 54.4 (48.7 to 60.0) 72.4 (64.4 to 79.4) 1.97 (1.46 to 2.40) 0.63 (0.58 to 0.74)
4 21.5 (16.6 to 27.2) 93.7 (89.6 to 96.4) 3.41 (1.83 to 4.97) 0.84 (0.78 to 0.90)
McIsaac score
0 99.7 (99.0 to 99.9) 2.3 (0.3 to 10.7) 1.02 (1.00 to 1.10) 0.15 (0.09 to 0.35)
1 97.5 (94.7 to 99.0) 10.8 (2.8 to 28.4) 1.09 (1.02 to 1.30) 0.23 (0.17 to 0.39)
2 88.0 (82.0 to 93.8) 31.5 (14.2 to 54.3) 1.30 (1.09 to 1.76) 0.35 (0.28 to 0.47)
3 68.7 (57.4 to 78.5) 60.8 (39.9 to 78.8) 1.75 (1.28 to 2.79) 0.51 (0.44 to 0.58)
4 40.0 (28.5 to 52.5) 84.8 (70.8 to 93.4) 2.64 (1.68 to 4.95) 0.71 (0.62 to 0.78)
5 16.1 (8.9 to 26.2) 96.3 (90.8 to 98.7) 4.32 (2.38 to 10.0) 0.87 (0.79 to 0.93)
CI = confidence interval. LR+ = positive likelihood ratio. LR– = negative likelihood ratio.
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provide evidence on each criteria's likely 
performance in practice and when they are 
most likely to be useful to clinicians. 
As a reference standard, the throat swab 
has limitations — its performance may 
depend on the operator and the conditions 
for incubation.38 Alternative reference 
standards, such as a rising titre of the 
antistreptolysin O (ASO) antibody, may be 
used, but these also vary with age, prevalence 
of streptococcus, and comorbidities.38 ASO 
testing is also rarely used by investigators; 
none of the included studies — or those 
excluded due to inadequacy of a reference 
test — used ASO testing.
The model used in this review benefits 
from being able to aggregate studies 
that provide data at multiple thresholds; 
however, this needs to be weighed against 
the necessity for continuity corrections when 
there are 0 cell entries in the 2 × 2 tables. 
Furthermore, at present, it is not clear how 
the DIDS model could include study-level 
covariates to investigate potential sources 
of heterogeneity.
Some authors have recommended the 
use of level-specific likelihood ratios.39 
This requires defining test positives as test 
results that equal the threshold score only, 
not the threshold score and above, as is 
usual practice. This alternative definition 
of a test positive leads to an important 
property of a ROC curve (monotonicity) 
being violated;40 hence, with the approach 
used here, it is not possible to estimate 
level-specific likelihood ratios.
As part of internal validation, the authors 
used bootstrap methods to correct the 
calibration plots for optimism. Other 
methods have been proposed that use 
leave-one-out cross-validation to derive a 
validation statistic so the internal validity of 
the summary estimates may be assessed;41 
it is also possible to use other information, 
such as the test positive rate, to derive an 
estimate that is tailored to the setting of 
interest.42,43 However, a shortcoming with 
all of these methods, including the method 
used here, is that they are rarely subject to 
external validation; without this, it is difficult 
to make assertions on the transferability of 
the results.
Comparison with existing literature
A recent review of guidelines for diagnosing 
acute pharyngitis44 revealed that both the 
Centor and McIsaac prediction scores are 
incorporated into guidance for Europe and 
North America. The Centor score is one 
of two prediction rules recommended for 
managing patients with a sore throat in the 
UK,10 while, in Denmark9 and Germany,8 
the McIsaac score is recommended. 
This demonstrates that these scores are 
considered relevant to the diagnosis of 
acute pharyngitis in a number of countries. 
Therefore, it is perhaps surprising that only 
two reviews17,18 have evaluated the Centor 
score in primary care and no systematic 
review has evaluated the McIssac score 
in primary care. None of the reviews to 
date have used a model that was able 
to accommodate data from multiple 
thresholds per study in the analysis. Previous 
reviews17,18 have treated each threshold 
separately when aggregating studies, 
thereby ignoring potential correlations 
between thresholds at a primary-study level 
and at an SROC curve level. Furthermore, 
none of the reviews have sought to establish 
how well the prediction rules calibrate in 
practice.
As a comparison, the two previous 
reviews on the Centor score reported 
positive likelihood ratios for a threshold 
of 3 — 2.68 (95% CI = 1.92 to 3.75)17 and 
2.35 (95% CI = 1.51 to 3.67)18 — and these 
were inflated compared with the ratios 
presented here. However, the negative 
likelihood ratios for a threshold of 1 were 
comparable: 0.27 (95% CI = 0.16 to 0.46)17 
and 0.28 (95% CI = 0.23 to 0.45).18
NICE has recently recommended using 
either the Centor or the FeverPAIN score 
perfect calibration between
the expected and observed PPVs
McIsaac score
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Figure 5. Calibration plots (corrected for optimism) 
for the Centor and McIsaac scores for a positive test 
result when the prevalence of GABHS is assumed 
to be known. GABHS = group A beta-haemolytic 
streptococcus. PPV = positive predictive value.
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to assess the symptoms of patients with 
acute pharyngitis.10 Although the latter was 
derived from a UK population, to date this 
is the only study on FeverPAIN25 and it is 
yet to be replicated in other independent 
populations; however, it is unclear whether 
the FeverPAIN score would lead to a 
marked improvement in discrimination 
and calibration, particularly when it shares 
many of the covariates of the scores that 
were reviewed here.
Implications for practice
Although the Centor score showed better 
calibration than the McIsaac system for a 
negative result, perhaps of more relevance 
is that, for estimated probabilities of <20%, 
the observed probabilities of GABHS in 
practice, given a negative test result, are 
consistently lower than the corresponding 
estimates. On this basis, a Centor score 
of 0 or a McIsaac score of ≤0 is likely to 
correspond to an actual risk of GABHS that 
is lower than the expected risk of 8.5% — as 
such, it is likely to be sufficient to rule out 
infection.
For a Centor or a McIsaac score of ≥1, 
it is less clear how to proceed. In general, 
the probability of GABHS for these scores 
is likely to be too high (>10%) to rule out 
infection and too low to rule in infection. 
NICE’s current recommendation is that a 
Centor score of ≥3 is sufficient grounds 
to consider prescribing antibiotics either 
immediately or as a delayed script 
with advice;10 however, the evidence 
presented here suggests that neither 
score can realistically identify patients 
with an observed risk of GABHS of >50%, 
irrespective of the expected risk. There is 
the potential that these recommendations 
could lead to inappropriate prescribing of 
antibiotics in a large percentage of cases.
In all instances, the GP should weigh up 
the public-health need to reduce the number 
of inappropriate antibiotic prescriptions 
and the individual patient’s need to treat 
a potential infection. With this in mind, an 
honest discussion with the patient about the 
likely GABHS risk and the GP’s obligation 
not to prescribe antibiotics inappropriately 
before deciding on management seems the 
most reasonable way to proceed.
Any substantive improvement in the 
diagnosis of GABHS-related pharyngitis is 
likely to require either a new prediction 
system or the use of point-of-care 
technologies to augment the existing 
clinical prediction tools.45
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